ES2829637T3 - 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné - Google Patents

3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné Download PDF

Info

Publication number
ES2829637T3
ES2829637T3 ES15816887T ES15816887T ES2829637T3 ES 2829637 T3 ES2829637 T3 ES 2829637T3 ES 15816887 T ES15816887 T ES 15816887T ES 15816887 T ES15816887 T ES 15816887T ES 2829637 T3 ES2829637 T3 ES 2829637T3
Authority
ES
Spain
Prior art keywords
compound
dihydroxy
stilbene
isopropyl
acne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15816887T
Other languages
English (en)
Spanish (es)
Inventor
Javier Cote-Sierra
Susan H Smith
Steven M Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermavant Sciences GmbH
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Application granted granted Critical
Publication of ES2829637T3 publication Critical patent/ES2829637T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15816887T 2014-12-12 2015-12-09 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné Active ES2829637T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462090908P 2014-12-12 2014-12-12
PCT/IB2015/059490 WO2016092493A1 (en) 2014-12-12 2015-12-09 Novel method of use

Publications (1)

Publication Number Publication Date
ES2829637T3 true ES2829637T3 (es) 2021-06-01

Family

ID=55025296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15816887T Active ES2829637T3 (es) 2014-12-12 2015-12-09 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné

Country Status (11)

Country Link
US (1) US10376475B2 (enExample)
EP (1) EP3229840B1 (enExample)
JP (3) JP7313117B2 (enExample)
KR (1) KR102607222B1 (enExample)
AR (1) AR102973A1 (enExample)
AU (1) AU2015358910B2 (enExample)
CA (1) CA2970739C (enExample)
DK (1) DK3229840T5 (enExample)
ES (1) ES2829637T3 (enExample)
TW (1) TWI692357B (enExample)
WO (1) WO2016092493A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
CR20170528A (es) 2015-05-21 2018-01-22 Glaxosmithkline Ip Dev Ltd Composiciones farmacéuticas tópicas.
US20170231922A1 (en) * 2016-02-16 2017-08-17 Horizon GenoMed Therapeutics, Inc 3, 5-dihydroxy-4-isopropylstilbene (dhis) as miticidal agent and its therapeutic uses
EP3706725A4 (en) 2017-11-10 2021-08-25 Dermavant Sciences GmbH PROCESS FOR THE PREPARATION OF TAPINAROF
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
WO2020174467A1 (en) * 2019-02-25 2020-09-03 Sol-Gel Technologies Ltd. Treatment of psoriasis with topical tapinarof- tazarotene combination compositions
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
US20220287990A1 (en) * 2019-07-24 2022-09-15 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
US20220331268A1 (en) * 2019-09-26 2022-10-20 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
JP2023503132A (ja) * 2019-11-24 2023-01-26 ソル － ゲル テクノロジーズ リミテッド タピナロフおよびｐｄｅ４阻害剤を含む局所用組成物による皮膚障害の治療
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经系统相关疾病的化合物
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003695A1 (en) 1993-07-27 1995-02-09 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria xenorhabdus and photorhabdus spp.
US5747482A (en) * 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
JP4880847B2 (ja) 1999-12-06 2012-02-22 ウェリケム，バイオテック インコーポレーテッド ヒドロキシルスチルベンならびに新規スチルベン誘導体および類似体による抗炎症治療および乾癬治療ならびにプロテインキナーゼ阻害
US7321050B2 (en) * 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
CN1688535B (zh) * 2002-10-01 2011-11-09 北京文丰天济医药科技有限公司 新型生物活性的二苯乙烯化合物及其医疗用途
FR2917427B1 (fr) * 2007-06-18 2009-08-21 Galderma Res & Dev Inhibiteurs de tace dans le traitement de l'acne
US9308239B2 (en) * 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
CN101531571B (zh) 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
CN101633606B (zh) 2009-08-13 2014-08-27 河北科技大学 盐酸非均相氯代合成茋类化合物的方法
CN101648851B (zh) 2009-09-03 2012-10-10 河北科技大学 (e)-3,5-二羟基-4-异丙基二苯乙烯的清洁制备方法
CN101830764A (zh) 2010-05-05 2010-09-15 河北科技大学 利用Pfitzner-moffatt氧化反应合成茋类化合物的方法
CN101838173A (zh) 2010-05-07 2010-09-22 河北科技大学 利用Kornblum氧化反应合成茋类化合物的方法
KR102066295B1 (ko) * 2011-06-27 2020-01-14 갈데르마 리써어치 앤드 디벨로프먼트 신규한 여드름용 ｔｈ１７ 분화 마커 및 이의 용도

Also Published As

Publication number Publication date
JP2021152018A (ja) 2021-09-30
TWI692357B (zh) 2020-05-01
AU2015358910B2 (en) 2019-01-24
DK3229840T3 (da) 2020-11-09
JP7313117B2 (ja) 2023-07-24
US10376475B2 (en) 2019-08-13
KR102607222B1 (ko) 2023-11-29
EP3229840A1 (en) 2017-10-18
KR20170095928A (ko) 2017-08-23
AR102973A1 (es) 2017-04-05
US20170360719A1 (en) 2017-12-21
AU2015358910A1 (en) 2017-06-29
DK3229840T5 (da) 2020-11-16
TW201639548A (zh) 2016-11-16
CA2970739C (en) 2023-10-03
EP3229840B1 (en) 2020-09-09
JP2023123554A (ja) 2023-09-05
WO2016092493A1 (en) 2016-06-16
CA2970739A1 (en) 2016-06-16
JP2017537936A (ja) 2017-12-21

Similar Documents

Publication Publication Date Title
ES2829637T3 (es) 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné
JP6944399B2 (ja) プロバイオティクス細菌
Han et al. The antimicrobial effect of CEN1HC-Br against Propionibacterium acnes and its therapeutic and anti-inflammatory effects on acne vulgaris
US20230165915A1 (en) Materials and methods for improving immune responses and skin and/or mucosal barrier functions
US20150017227A1 (en) Methods and Compositions for Treating Skin Diseases and Conditions
EP3479831B1 (en) Composition comprising thrombin-treated stem cell-derived exosome for use in treating skin wound
KR20100016450A (ko) 피부 외용제 조성물
CN102256608A (zh) 含有血单核细胞培养物的上清液的药物制剂
RU2687151C2 (ru) Тетрапептиды, полученные из с-х-с-хемокинов человека, подходящие для лечения различных состояний кожи
CN114080230A (zh) 氧化低渗酸溶液的治疗用途
CA3064050A1 (en) Extracts from arthrospira and uses thereof
Chen et al. Effects of rhynchophylline and isorhynchophylline on nitric oxide and endothelin-1 secretion from RIMECs induced by Listeriolysin O in vitro
ES2447040T3 (es) Utilización de ésteres de alquilglucósido como inductores de beta-defensinas
TW201711696A (zh) 用於促進傷口癒合的吳郭魚抗菌胜肽
RU2822544C2 (ru) Терапевтическое применение окислительных гипотонических кислотных растворов
US12239681B2 (en) Formulations and methods for skin care
Arnke The role of MIF-2 in obesity-induced wound healing disorder
Tomii et al. 965 The importance of CD206+ macrophages in squaric acid dibutylester-induced hair cycle activation
Raghavan et al. 964 Epidermis derived lactate promotes sterile inflammation by inducing metabolic rewiring in macrophages
Kosaka et al. 963 Linear ubiquitin chain assembly complex (LUBAC) is involved in the development of murine imiquimod (IMQ)-induced and IL-23-induced psoriasis models
Dinic et al. 961 Opportunist turns pathogen: Multidrug resistant Staphylococcus epidermidis is associated with the wound chronicity
Aldehalan et al. 960 A metabolite produced by skin commensal bacteria enhances epithelial integrity in human keratinocyte
Urata et al. 962 Administration of IL-31 induces anxiety-like behavior in mice
Tran Effect of Oxyresveratrol on Inflammatory Skin Diseases||
CN121370715A (zh) 一种用于延缓细胞衰老、维持组织稳态的组合物及其制备方法和应用